MHRA-100128-PIP01-21-M02 (update)

Key Facts

Active Substance
Active Substance:
  • tiomolibdic acid
Invented Name
Not yet available
PIP Number MHRA-100128-PIP01-21-M02 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Coated tablet Age-appropriate oral solid dosage form
Therapeutic area
Therapeutic area:
  • Endocrinology-Gynaecology-Fertility-metabolism
Conditions / Indications
Conditions / Indications:
  • Wilson disease
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):tiomolibdic acid.pdf
Published Date 25/05/2023